The IL-23, IL-10, and TGF-β1 levels were significantly higher in patients with CIS than in patients with OND (p = 0.015, p < 0.001, and p = 0.022, respectively; Figures 2A–C). This evidence concerns the gene IL10 and in situ carcinoma.